JPH05505596A - 尿中腫瘍関連抗原、抗原性サブユニットの使用および検出方法 - Google Patents
尿中腫瘍関連抗原、抗原性サブユニットの使用および検出方法Info
- Publication number
- JPH05505596A JPH05505596A JP91500470A JP50047091A JPH05505596A JP H05505596 A JPH05505596 A JP H05505596A JP 91500470 A JP91500470 A JP 91500470A JP 50047091 A JP50047091 A JP 50047091A JP H05505596 A JPH05505596 A JP H05505596A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- taa
- antibody
- antigen
- urinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 199
- 239000000427 antigen Substances 0.000 title claims description 193
- 108091007433 antigens Proteins 0.000 title claims description 193
- 102000036639 antigens Human genes 0.000 title claims description 193
- 230000002485 urinary effect Effects 0.000 title claims description 65
- 230000000890 antigenic effect Effects 0.000 title claims description 29
- 238000001514 detection method Methods 0.000 title claims description 16
- 210000004027 cell Anatomy 0.000 claims description 125
- 210000002700 urine Anatomy 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 95
- 201000001441 melanoma Diseases 0.000 claims description 89
- 210000002966 serum Anatomy 0.000 claims description 84
- 201000011510 cancer Diseases 0.000 claims description 52
- 239000003153 chemical reaction reagent Substances 0.000 claims description 50
- 210000004881 tumor cell Anatomy 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 37
- 229960005486 vaccine Drugs 0.000 claims description 35
- 241001504519 Papio ursinus Species 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 14
- 210000001124 body fluid Anatomy 0.000 claims description 13
- 239000010839 body fluid Substances 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 13
- 230000003302 anti-idiotype Effects 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 230000009467 reduction Effects 0.000 claims description 12
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 10
- 238000009169 immunotherapy Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000002853 nucleic acid probe Substances 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 238000001502 gel electrophoresis Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 241001669573 Galeorhinus galeus Species 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 238000001879 gelation Methods 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 description 55
- 238000003556 assay Methods 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 238000002965 ELISA Methods 0.000 description 25
- 230000000735 allogeneic effect Effects 0.000 description 25
- 241001529936 Murinae Species 0.000 description 24
- 230000009257 reactivity Effects 0.000 description 24
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 22
- 238000010790 dilution Methods 0.000 description 20
- 239000012895 dilution Substances 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 19
- 230000004044 response Effects 0.000 description 14
- 230000009102 absorption Effects 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000009977 dual effect Effects 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000006037 cell lysis Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000005875 antibody response Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 229940109239 creatinine Drugs 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 8
- 241000283707 Capra Species 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 7
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000012506 Sephacryl® Substances 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 206010000269 abscess Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 102000007592 Apolipoproteins Human genes 0.000 description 5
- 108010071619 Apolipoproteins Proteins 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 230000002391 anti-complement effect Effects 0.000 description 5
- 108010008730 anticomplement Proteins 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940044627 gamma-interferon Drugs 0.000 description 4
- 238000001641 gel filtration chromatography Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010061819 Disease recurrence Diseases 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000003127 anti-melanomic effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 241001253206 Andrias Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- -1 B2-glycoprotein Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010073573 Colonic abscess Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101710123026 High molecular weight antigen Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036624 brainpower Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000000684 melanotic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical group [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108091008020 response regulators Proteins 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 229940030325 tumor cell vaccine Drugs 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.約90から100kDの分子量を有する尿中腫瘍関連抗原の実質的に精製さ れた抗原性のポリペプチドサブユニットであって、該分子量が、β−メルカプト エタノールによる還元およびSDS−ポリアクリルアミドゲル電気泳動法による 分離の後に測定された、ポリペプチドサブユニット。 2.請求項1に記載のポリペプチドに曝された動物由来の抗体産生細胞を単離す ること、該抗体産生細胞と癌細胞との間のハイプリドーマを形成すること、およ び該ポリペプチドと反応する抗体を産生する細胞を選択することによって産生さ れるモノクローナル抗体。 3.被験者における癌を検出する方法であって、該被験者の体液由来の尿中腫瘍 関連抗原を請求項2に記載のモノクローナル抗体と接触させること、および該結 合した抗体の存在、すなわち、癌の存在を示す尿中腫瘍関連抗原の存在を検出す ることを包含する、方法。 4.前記癌が潜在性である、請求項3に記載の方法。 5.IgGおよびlgMでなる群から選択される、請求項2に記載のモノクロー ナル抗体。 6.尿中腫瘍関連抗原と反応する抗体と反応する試薬。 7.抗イデオタイプの抗体である、請求項6に記載の試薬。 8.請求項7の抗イデオタイプの抗体の治療上の量を被験者に注射することを包 含する、免疫治療の方法。 9.悪性腫瘍をモニターする方法であって、請求項2のモノクローナル抗体を、 病気の被験者の体液由来の尿中腫瘍関連抗原と接触させること、所定の量の体液 に対する尿中腫瘍関連抗原の量を決定すること、該量と、同等の試料のために予 め決定された量とを比較することを包含する方法であって、尿中腫瘍関連抗原の 差異が該悪性腫瘍の状態の度合を示す、方法。 10.バイオプシーの腫瘍細胞上の尿中腫瘍関連抗原を検出する方法であって、 請求項2に記載のモノクローナル抗体を腫瘍細胞と接触させること、および該結 合した抗体の存在を検出することを包含する、方法。 11.腫瘍細胞に対して向けられる、抗体または細胞が媒介する免疫を誘導する ための、あるいは増強するためのワクチンであって、細胞表面に尿中腫瘍関連抗 原を有する不活性化された腫瘍細胞、およびGM−2、GD−2、胎児の抗原、 またはメラノーマ腫瘍関連抗原でなる群から選択される、少なくとも1種の腫瘍 開運抗原、および薬学上受容し得る担体を含有する、ワクチン。 12.前記腫瘍細胞が、UCLA−SO−M10、UCLA−SO−M24およ びUCLA−SO−M101でなる群から選択されるメラノーマ細胞である、請 求項11に記載のワクチン。 13.前記細胞が、さらに該細胞表面に被験者と同様のタイプのHLAを有する 、請求項11に記載のワクチン。 14.被験者において約90から100kDの分子量を有する尿中腫瘍関連抗原 のポリペプチドサブユニットと反応する抗体の産生を誘導するための、あるいは 増強するための方法であって、該分子量が、βメルカプトエタノールによる還元 およびSDS−ポリアクリルアミドゲル電気泳動法による分離の後に測定された 方法であって、請求項11に記載のワクチンの有効量を該被験者に投与すること を包含する、方法。 15.前記被験者が、ヒトである、請求項14に記載の方法。 16.前記被験者が癌を患っており、そして前記ワクチンの投与後に各個体にお いて産生された前記抗体が該癌を抑制する、請求項14に記載の方法。 17.前記癌がメラノーマ、サルコーマおよびカルシノーマでなる群から選択さ れる、請求項16に記載の方法。 18.請求項1に記載のポリペプチドおよび薬学上受容し得る担体を含有する、 ワクチン。 19.被験者において、該被験者における腫瘍細胞と反応する抗体の産生を誘導 するための、あるいは増強するための方法であって、請求項18に記載のワクチ ンを投与することを包含する、方法。 20.被験者において、胸部または肺のカルシノーマを検出する方法であって、 該被験者の試料由来の尿中腫瘍関連抗原の存在を検出することを包含する、方法 。 21.前記検出が、尿中腫瘍関連抗原を抗体と結合させること、および該抗体の 存在を検出することを包含する、請求項20に記載の方法。 22.被験者において腫瘍をインビボで検出する方法であって、該腫瘍細胞表面 上の尿中腫瘍関連抗原と反応する試薬を該被験者に注射すること、該尿中腫瘍関 連抗原と反応する該試薬の存在を検出すること、およびそれによって該腫瘍を検 出することを包含する、方法。 23.前記腫瘍が、メラノーマ、サルコーマ、またはカルシノーマでなる群から 選択される、請求項22に記載の方法。 24.前記試薬が抗体である、請求項23に記載の方法。 25.前記抗体がモノクローナルである、請求項24に記載の方法。 26.被験者中の腫瘍細胞表面に尿中腫瘍関連抗原を発現する腫瘍を抑制する方 法であって、該腫瘍細胞表面の尿中腫瘍関連抗原と反応する、腫瘍を抑制する試 薬を該被験者に注射することを包含する、方法。 27.前記試薬が抗体である、請求項26に記載の方法。 28.前記抗体が細胞毒性または細胞増殖抑制性の薬剤に結合している、請求項 27に記載の方法。 29.前記細胞毒性または細胞増殖抑制性の薬剤が、毒素、放射線標識された成 分、および化学療法薬でなる群から選択される、請求項28に記載の方法。 30.請求項1に記載のポリペプチドをコードする核酸。 31.請求項30に記載の核酸と選択的にハイブリダイズし得る核酸プローブ。 32.請求項1に記載のポリペプチドの抗原性の部分をコードする核酸。 33.前記核酸が、抗イデオクイブの抗体における抗原性の部分の配列に対応す る、請求項32に記載の核酸。 34.請求項33に記載の核酸と選択的にハイブリダイズし得る核酸のプローブ 。 35.低レベルの尿中腫瘍関連抗原を検出する方法であって、γ−インターフェ ロンで癌細胞における尿中腫瘍関連抗原の発現を増強すること、該尿中腫瘍関連 抗原を試薬と接触させること、および該試薬の存在を検出することを包含する、 方法。 36.被験者において癌を診断する方法であって、被験者の体液において請求項 1に記載のポリペプチドを検出することを包含する、方法。 37.前記検出することが、前記ポリペプチドと試薬とを接触させること、およ び核ポリペプチドと反応する該試薬の存在を検出することを包含する、方法。 38.以下の(1)、(2)および(3)を包含する、癌から得られる尿中抗原 性複合体(urinary antigenic complex)を有する被 験者において癌を検出またはモニターする方法:(1)該被験者から試料を除去 すること;(2)尿中腫瘍関連抗原に結合する試薬と結合することを妨げるため に、該試料中の該尿中抗原性複合体の炭水化物部分を政変すること;および (3)該改変された尿中抗原性複合体の少なくとも一部を検出すること、および それによって該癌を検出すること。 39.45kDのポリペプチドサブユニットに位置した尿中腫瘍関連抗原のエピ トープであって、該ポリペプチドサブユニットの分子量がβ−メルカプトエタノ ールによる還元およびSDS−ポリアクリルアミドゲル電気泳動法による分離の 後に測定され、そして自己ヒト血清またはヒヒのポリクローナル抗体と反応する 、エピトープ。 40.120kDのポリペプチドサブユニットに位置した尿中腫瘍関連抗原のエ ピトープであって、該ポリペプチドサブユニットの分子量がβ−メルカプトエタ ノールによる還元およびSDS−ポリアクリルアミドゲル電気泳動法による分離 の後に測定され、そしてヒヒのポリクローナル抗体と反応する、エピトープ。 41.以下の(1)、(2)、(3)および(4)を包含する、試料における尿 中腫瘍関連抗原を検出する方法:(1)該尿中腫瘍関連抗原と、尿中腫瘍関連抗 原上のエピトープと結合する第一の試薬とを接触させること;(2)該尿中腫瘍 関連抗原と、尿中腫瘍関連抗原上の第二のエピトープと結合する第二の試薬とを 接触させること;(3)該試薬の1種を固体の支持体に結合させること;および (4)結合した試薬の存在を検出すること、およびそれによって尿中腫瘍関連抗 原の存在を検出すること、ここで、該試薬の1種は非ヒトポリクローナル抗体で ある。 42.前記試薬が両者とも抗体である、請求項41に記載の方法。 43.前記ポリクローナル抗体がヒヒから単離される、請求項41に記載の方法 。 44.前記試薬が、尿中腫瘍関連抗原上のエピトープと結合する前に、前記固体 の支持体と結合する、請求項41に記載の方法。 45.以下の(1)、(2)、(3)および(4)を包含する、試料において尿 中腫瘍関連抗原を検出する方法:(1)β−メルカプトエタノールによる還元お よびSDS−ポリアクリルアミドゲル電気泳動法による分離の後に確認される、 45、65、90−100および120kDのサブユニット上のエピトープでな る群から選択される、該尿中腫瘍関連抗原上のエピトープと結合する第一の試薬 を、尿中腫瘍関連抗原と接触させること; (2)β−メルカプトエタノールによる還元およびSDS−ポリアクリルアミド ゲル電気泳動法による分離の後に確認される、45、90−100および120 kDのサブユニット上のエビトープでなる群から選択される、該尿中腫瘍関連抗 原上のエピトープと結合する第二の試薬を尿中腫瘍関連抗原と接触させること; (3)該試薬の1種と固体の支持体とを結合させること;および (4)結合していない試薬の存在を検出すること、およびそれによって尿中腫瘍 関連抗原の存在を検出すること。 46.β−メルカプトエタノールによる還元およびSDS−ポリアクリルアミド ゲル電気泳動法による分離の後に測定された場合、65kDのポリペプチドサブ ユニットに位置する尿中腫瘍関連抗原のエピトープであって、自己ヒト血清また はヒヒのポリクローナル抗体と反応する、エピトープ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43153389A | 1989-11-03 | 1989-11-03 | |
US431,533 | 1989-11-03 | ||
PCT/US1990/006339 WO1991006866A2 (en) | 1989-11-03 | 1990-10-31 | Urinary tumor associated antigen, antigenic subunits uses and methods of detection |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001060998A Division JP3429281B2 (ja) | 1989-11-03 | 2001-03-05 | 尿中関連抗原、抗原サブユニットの使用および検出方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05505596A true JPH05505596A (ja) | 1993-08-19 |
JP3423306B2 JP3423306B2 (ja) | 2003-07-07 |
Family
ID=23712351
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50047091A Expired - Lifetime JP3423306B2 (ja) | 1989-11-03 | 1990-10-31 | 尿中腫瘍関連抗原、抗原性サブユニットの使用および検出方法 |
JP2001060998A Expired - Fee Related JP3429281B2 (ja) | 1989-11-03 | 2001-03-05 | 尿中関連抗原、抗原サブユニットの使用および検出方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001060998A Expired - Fee Related JP3429281B2 (ja) | 1989-11-03 | 2001-03-05 | 尿中関連抗原、抗原サブユニットの使用および検出方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US5993828A (ja) |
EP (2) | EP0498851B1 (ja) |
JP (2) | JP3423306B2 (ja) |
AT (2) | ATE132629T1 (ja) |
AU (1) | AU661816B2 (ja) |
CA (2) | CA2331088A1 (ja) |
DE (2) | DE69033295T2 (ja) |
DK (1) | DK0498851T3 (ja) |
ES (2) | ES2138102T3 (ja) |
WO (1) | WO1991006866A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2044421C (en) * | 1990-11-27 | 2005-06-21 | Thomas Hyatt Duffy | Squamous cell carcinoma-like immunoreactive antigen from human female urine |
US6218166B1 (en) * | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
GB9806104D0 (en) * | 1998-03-20 | 1998-05-20 | Smithkline Beecham Biolog | Novel compounds |
GB9924351D0 (en) | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
ES2347762T3 (es) | 2000-04-28 | 2010-11-04 | Mannkind Corporation | Sincronizacion de epitopos en celulas que presentan antigenos. |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
AUPQ755300A0 (en) * | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
EP1752160A3 (en) | 2001-04-06 | 2007-05-30 | Mannkind Corporation | Epitope sequences |
AU2002327037A1 (en) | 2001-09-20 | 2003-04-01 | Board Of Regents, The University Of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
DE60238864D1 (de) | 2001-11-07 | 2011-02-17 | Mankind Corp | Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption |
WO2003052144A1 (en) * | 2001-12-14 | 2003-06-26 | Cygene, Inc. | Diagnostic assays for bcwa |
JP2005537800A (ja) * | 2002-09-06 | 2005-12-15 | マンカインド コーポレイション | エピトープ配列 |
GB2424070B (en) * | 2002-11-14 | 2007-06-27 | Univ Nottingham | Methods for preparing tumour marker proteins |
US7176022B2 (en) | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
SG158154A1 (en) * | 2004-12-29 | 2010-01-29 | Mannkind Corp | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
WO2007112316A2 (en) * | 2006-03-24 | 2007-10-04 | Morton Donald L | Mycobacterial immunotherapy for cancer treatment |
CA2659270A1 (en) * | 2006-07-28 | 2008-01-31 | Novartis Ag | Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma |
EP3084445B1 (en) | 2013-12-11 | 2020-10-28 | University of Massachusetts | Compositions and methods for treating disease using salmonella t3ss effector protein (sipa) |
EP3767629A4 (en) | 2018-03-16 | 2022-01-19 | KOTAI Biotechnologies, Inc. | EFFICIENT GROUPING OF IMMUNOLOGICAL ENTITIES |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1603406A (en) * | 1977-08-31 | 1981-11-25 | Nat Res Dev | Assay of immune complexes |
US4348376A (en) * | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
JPS5915858A (ja) * | 1982-07-16 | 1984-01-26 | Otsuka Pharmaceut Co Ltd | 腫瘍関連抗原特異的免疫複合体の測定法 |
US4806628A (en) * | 1982-11-30 | 1989-02-21 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies against melanocytes |
US4557931A (en) * | 1982-12-02 | 1985-12-10 | Regents Of The University Of California | Antigenic compositions and methods for using same |
US4562160A (en) * | 1983-04-01 | 1985-12-31 | Sloan-Kettering Institute | Melanoma tumor antigen and autologous antibody |
SE8401945L (sv) * | 1983-04-08 | 1984-11-13 | Kureha Chemical Ind Co Ltd | Antikropp mot cancer i urinblasan hos menniska |
US4828991A (en) * | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US4707438A (en) * | 1984-08-22 | 1987-11-17 | Tel Aviv University | Immunoassay for breast cancer employing monoclonal antibodies |
US5614610A (en) * | 1984-12-21 | 1997-03-25 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
US4753884A (en) * | 1986-01-28 | 1988-06-28 | Novagene, Inc. | Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same |
GB2188637B (en) * | 1986-02-07 | 1990-11-14 | Oncogen | Vaccines against melanoma |
US5292636A (en) * | 1986-03-31 | 1994-03-08 | T Cell Diagnostics, Inc. | Therapeutic and diagnostic methods using soluble T cell surface molecules |
US4895817A (en) * | 1986-05-09 | 1990-01-23 | The Goodyear Tire & Rubber Company | Polycondensation catalyst |
US5401638A (en) * | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4810781A (en) * | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
US5030621A (en) * | 1987-04-23 | 1991-07-09 | Bystryn Jean Claude | Shed melanoma antigen compositions |
US5194384A (en) * | 1987-04-23 | 1993-03-16 | Bystryn Jean Claude | Method for preparing human meloma vaccine |
US4946774A (en) * | 1987-11-09 | 1990-08-07 | Trustees Of Boston University | Process for detecting cancer and for monitoring the effectiveness of cancer therapy |
US5250297A (en) * | 1989-10-20 | 1993-10-05 | Hybritech Incorporated | Tumor-associated antigen, antibodies, compositions and uses therefor |
US5427664A (en) * | 1993-07-22 | 1995-06-27 | Stoev; Stoyan V. | Free solution electrophoresis-membrane filters trapping assay apparatus and method |
DK0668350T4 (da) * | 1994-02-16 | 2009-02-23 | Us Gov Health & Human Serv | Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom |
-
1990
- 1990-10-31 JP JP50047091A patent/JP3423306B2/ja not_active Expired - Lifetime
- 1990-10-31 DE DE69033295T patent/DE69033295T2/de not_active Expired - Fee Related
- 1990-10-31 EP EP90917644A patent/EP0498851B1/en not_active Expired - Lifetime
- 1990-10-31 CA CA002331088A patent/CA2331088A1/en not_active Abandoned
- 1990-10-31 CA CA002072620A patent/CA2072620C/en not_active Expired - Lifetime
- 1990-10-31 DK DK90917644.8T patent/DK0498851T3/da active
- 1990-10-31 DE DE69024659T patent/DE69024659T2/de not_active Expired - Lifetime
- 1990-10-31 EP EP95104918A patent/EP0678744B1/en not_active Expired - Lifetime
- 1990-10-31 AT AT90917644T patent/ATE132629T1/de not_active IP Right Cessation
- 1990-10-31 ES ES95104918T patent/ES2138102T3/es not_active Expired - Lifetime
- 1990-10-31 AT AT95104918T patent/ATE184704T1/de not_active IP Right Cessation
- 1990-10-31 ES ES90917644T patent/ES2084715T3/es not_active Expired - Lifetime
- 1990-10-31 WO PCT/US1990/006339 patent/WO1991006866A2/en active IP Right Grant
- 1990-10-31 AU AU68753/91A patent/AU661816B2/en not_active Expired
-
1995
- 1995-06-05 US US08/462,570 patent/US5993828A/en not_active Expired - Fee Related
- 1995-06-05 US US08/462,264 patent/US5700649A/en not_active Expired - Lifetime
-
2001
- 2001-03-05 JP JP2001060998A patent/JP3429281B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3423306B2 (ja) | 2003-07-07 |
DE69033295T2 (de) | 2000-05-25 |
DK0498851T3 (da) | 1996-05-13 |
ES2138102T3 (es) | 2000-01-01 |
DE69024659D1 (de) | 1996-02-15 |
AU6875391A (en) | 1991-05-31 |
ATE132629T1 (de) | 1996-01-15 |
EP0498851B1 (en) | 1996-01-03 |
CA2331088A1 (en) | 1991-05-04 |
JP2001281255A (ja) | 2001-10-10 |
EP0678744A3 (en) | 1995-12-13 |
US5993828A (en) | 1999-11-30 |
AU661816B2 (en) | 1995-08-10 |
EP0678744A2 (en) | 1995-10-25 |
JP3429281B2 (ja) | 2003-07-22 |
DE69033295D1 (de) | 1999-10-21 |
WO1991006866A3 (en) | 1991-09-05 |
US5700649A (en) | 1997-12-23 |
CA2072620A1 (en) | 1991-05-04 |
DE69024659T2 (de) | 1996-11-07 |
CA2072620C (en) | 2007-06-12 |
ATE184704T1 (de) | 1999-10-15 |
EP0498851A1 (en) | 1992-08-19 |
ES2084715T3 (es) | 1996-05-16 |
WO1991006866A2 (en) | 1991-05-16 |
EP0678744B1 (en) | 1999-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05505596A (ja) | 尿中腫瘍関連抗原、抗原性サブユニットの使用および検出方法 | |
US4446122A (en) | Purified human prostate antigen | |
JP2520107B2 (ja) | 胃腸管癌のインビトロ検出 | |
USRE33405E (en) | Purified human prostate antigen | |
JPH04502328A (ja) | シクロスポリンaの新規誘導体、それに対する抗体及びその使用 | |
Lambin et al. | Adverse Transfusion Reactions Associated with a Precipitating Anti-C4 Antibody of Anti-Rodgers Specificity1 | |
JPH05500600A (ja) | スフィンゴ糖脂質に対する免疫応答を誘導する抗イディオタイプ抗体及びその使用 | |
JPH0742320B2 (ja) | 転移性ヒト腫瘍を確認する方法および組成物 | |
US5824640A (en) | Substances of polypeptide nature useful in human therapy | |
AU593229B2 (en) | Onco-fetal specific monoclonal antibodies methods of preparation and use | |
JPH04505401A (ja) | 主要組織適合抗原に会合したペプチドを認識するモノクローナル抗体 | |
WO1981001849A1 (en) | Purified human prostate antigen | |
Cantrell et al. | Correlations between humoral immunity and successful chemotherapy-immunotherapy | |
US6491926B1 (en) | 35 kD tumor associated protein antigen: uses and methods of detection | |
Morgan et al. | “Hidden” cytotoxic antibodies that react with allogeneic cultured fetal and tumor cells contained in soluble immune complexes from normal human sera | |
PT95856B (pt) | Processo para a preparacao de novos anticorpos monoclonais anti-idiotipicos | |
KR900004436B1 (ko) | 항-이디오형 항체 | |
JPH03504323A (ja) | 抗体 | |
Diederichsen et al. | Antibodies to Isolated Hepatocytes in Chronic Active Liver Disease: Identification and Diagnostic Significance of Bile Canalicular Antibodies | |
JPH0343078A (ja) | 新規ハイブリドーマ,モノクローナル抗体および用途 | |
JPH08208698A (ja) | モノクローナル抗体 | |
JPH0630620B2 (ja) | 人体液中に存在する分子量7万〜30万のコリンエステラーゼに反応するモノクローナル抗体 | |
Ran et al. | The relationship of membrane antigens on 141 (NZB) and EL4 (C57BL) lymphoma cells as demonstrated by antibodyinduced resistance to complement‐mediated cytotoxicity | |
EP0339632A2 (en) | Method of assaying human cancer antigens | |
JPS62207298A (ja) | 抗ヒト胃癌単クロ−ン性抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080425 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090425 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090425 Year of fee payment: 6 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090425 Year of fee payment: 6 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100425 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110425 Year of fee payment: 8 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110425 Year of fee payment: 8 |